Table 2.
Treatment-Related Adverse Events.
| Toxicity | Toxicity Category | Grade 3 N (%) |
Grade 4 N (%) |
|---|---|---|---|
| Alkaline phosphatase increased | Investigations | 1 (2.2) | - |
| Anemia | Blood and lymphatic system disorders | 1 (2.2) | - |
| Dizziness | Nervous system disorders | 1 (2.2) | - |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | 1 (2.2) | - |
| Fatigue | General disorders and administration site conditions | 6 (13.3) | - |
| General disorders and administration site conditions—Other, specify | General disorders and administration site conditions | - | 1 (2.2) |
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | 1 (2.2) | - |
| Hypertension | Vascular disorders | 1 (2.2) | - |
| Hypomagnesemia | Metabolism and nutrition disorders | 1 (2.2) | - |
| Hyponatremia | Metabolism and nutrition disorders | 1 (2.2) | - |
| Myocarditis | Cardiac disorders | 1 (2.2) | - |
| Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | 1 (2.2) | - |
| Rash acneiform | Skin and subcutaneous tissue disorders | 2 (4.4) | - |
| Rash maculo-papular | Skin and subcutaneous tissue disorders | 1 (2.2) | - |
| White blood cell decreased | Investigations | 1 (2.2) | - |
| Overall | 13 (28.9) | 1 (2.2) |